Navigation Links
Einstein researcher receives NIH grant to explore epigenetic regulation of the human genome
Date:10/16/2007

(BRONX, NY) A researcher at the Albert Einstein College of Medicine has been awarded a $1.5 million, three-year technology development grant from the National Human Genome Research Institute (NHGRI) of the National Institutes of Health. Dr. John Greally, associate professor of medicine and of molecular genetics at Einstein, received one of six technology development grants awarded by the NHGRI as part of its ENCyclopedia Of DNA Elements (ENCODE) project.

Dr. Greally studies epigenetics, an emerging field that involves changes in gene expression that do not result from changes in DNA sequence. These epigenetic changes can be passed on from one cell generation to the next. The epigenetic regulation of genesturning them on and offis crucially important: Glitches in epigenetic control mechanisms, for example, have been found in every type of cancer that researchers have examined to date.

During his three-year project, Dr. Greally plans to develop new means of identifying patterns of epigenetic regulators in the human genome, gaining insights into how these epigenetic mechanisms control genes. Dr. Greally will team with Brad Bernstein, M.D., of Massachusetts General Hospital and Andi Gnirke, Ph.D., of Bostons Broad Institute to develop these new assays that are based on the use of high-throughput sequencing.

The high-throughput sequencer will allow us to generate billions of base pairs of DNA sequence information in each experiment, allowing us to study the epigenome at a level of resolution that has never previously been possible, said Dr. Greally, who is principal investigator for the team. Well be able to view things in greater detail and with greater accuracy than ever before.

The researchers will be developing high-throughput methods to analyze and map the two principal epigenetic control mechanisms: methylation of cytosine (one of four nucleic acids found in DNA) and modifications of histones (proteins that help to package DNA into chromosomes). The methylation (addition of a methyl group, CH3) of cytosine switches genes off, which can be associated with certain diseases such as cancer. The second key epigenetic mechanismmodifying histone proteinsalso helps to control whether or not a gene is expressed.

The technology were using will allow us to identify the genetic mutations responsible for the epigenetic dysregulation that results in human disease, added Dr. Greally. In doing so, we can then develop potential targets for treatment.

All the data generated by the ENCODE project will be deposited into public databases as soon as they are experimentally verified. As a result, researchers around the world will have free and rapid access to the data and will be able to pose new questions and gain new insights into how the human genome functions.


'/>"/>

Contact: Karen Gardner
kgardner@aecom.yu.edu
718-430-3101
Albert Einstein College of Medicine
Source:Eurekalert

Related biology news :

1. Einstein researchers identify new way that bacteria develop resistance to antibiotics
2. Einstein scientists discover how protein crucial for motion is synthesised at the right place in the cell
3. Feinstein researchers identify intelligence gene
4. Study by Einstein researchers could lead to a novel strategy for treating obesity
5. Einstein researchers take the pulse of a gene in living cells
6. Einstein researchers demonstrate a novel approach to treating AIDS
7. Einsteins tea leaves inspire new blood separation technique
8. Researchers discover way to make cells in the eye sensitive to light
9. Researchers find how protein allows insects to detect and respond to pheromones
10. Researchers Uncover Key Step In Manufacture of Memory Protein
11. U of M researcher examines newly emerging deadly disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2016)... 28, 2016 First quarter 2016:   ... compared with the first quarter of 2015 The gross ... M (loss: 18.8) and the operating margin was 40% (-13) ... Cash flow from operations was SEK 249.9 M (21.2) , ... is unchanged, SEK 7,000-8,500 M. The operating margin for ...
(Date:4/15/2016)... April 15, 2016  A new partnership announced ... accurate underwriting decisions in a fraction of the ... priced and high-value life insurance policies to consumers ... With Force Diagnostics, rapid testing (A1C, Cotinine ... readings (blood pressure, weight, pulse, BMI, and activity ...
(Date:3/31/2016)...   LegacyXChange, Inc. ... LegacyXChange is excited to release its first ... be launched online site for trading 100% guaranteed authentic ... also provide potential shareholders a sense of the value ... industry that is notorious for fraud. The video is ...
Breaking Biology News(10 mins):
(Date:6/23/2016)... ... June 23, 2016 , ... Supplyframe, the Industry Network for ... Design Lab . Located in Pasadena, Calif., the Design Lab’s mission is to ... are designed, built and brought to market. , The Design Lab is Supplyframe’s ...
(Date:6/23/2016)... 2016 Apellis Pharmaceuticals, Inc. today announced ... of its complement C3 inhibitor, APL-2. The trials ... dose studies designed to assess the safety, tolerability, ... in healthy adult volunteers. Forty subjects ... single dose (ranging from 45 to 1,440mg) or ...
(Date:6/23/2016)... NEW YORK , June 23, 2016 ... the trading session at 4,833.32, down 0.22%; the Dow Jones ... the S&P 500 closed at 2,085.45, down 0.17%. Stock-Callers.com has ... INFI ), Nektar Therapeutics (NASDAQ: NKTR ... BIND Therapeutics Inc. (NASDAQ: BIND ). Learn more ...
(Date:6/23/2016)... ... June 23, 2016 , ... Velocity Products, a division ... tuned and optimized exclusively for Okuma CNC machining centers at The International Manufacturing ... collaboration among several companies with expertise in toolholding, cutting tools, machining dynamics and ...
Breaking Biology Technology: